chr16-28933379-G-T

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_001770.6(CD19):​c.705G>T​(p.Pro235Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.329 in 1,613,826 control chromosomes in the GnomAD database, including 92,518 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.28 ( 6874 hom., cov: 31)
Exomes 𝑓: 0.33 ( 85644 hom. )

Consequence

CD19
NM_001770.6 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: -2.29

Publications

32 publications found
Variant links:
Genes affected
CD19 (HGNC:1633): (CD19 molecule) This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
RABEP2 (HGNC:24817): (rabaptin, RAB GTPase binding effector protein 2) Predicted to enable GTPase activator activity and growth factor activity. Involved in regulation of cilium assembly. Located in cytosol; intracellular membrane-bounded organelle; and microtubule organizing center. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 16-28933379-G-T is Benign according to our data. Variant chr16-28933379-G-T is described in ClinVar as Benign. ClinVar VariationId is 318805.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-2.29 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.353 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_001770.6. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CD19
NM_001770.6
MANE Select
c.705G>Tp.Pro235Pro
synonymous
Exon 4 of 15NP_001761.3
CD19
NM_001178098.2
c.705G>Tp.Pro235Pro
synonymous
Exon 4 of 15NP_001171569.1
CD19
NM_001385732.1
c.438G>Tp.Pro146Pro
synonymous
Exon 3 of 14NP_001372661.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CD19
ENST00000538922.8
TSL:5 MANE Select
c.705G>Tp.Pro235Pro
synonymous
Exon 4 of 15ENSP00000437940.2
CD19
ENST00000324662.8
TSL:1
c.705G>Tp.Pro235Pro
synonymous
Exon 4 of 15ENSP00000313419.4
CD19
ENST00000565089.5
TSL:2
n.1039G>T
non_coding_transcript_exon
Exon 3 of 13

Frequencies

GnomAD3 genomes
AF:
0.276
AC:
41925
AN:
151942
Hom.:
6876
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.110
Gnomad AMI
AF:
0.423
Gnomad AMR
AF:
0.279
Gnomad ASJ
AF:
0.409
Gnomad EAS
AF:
0.191
Gnomad SAS
AF:
0.126
Gnomad FIN
AF:
0.442
Gnomad MID
AF:
0.367
Gnomad NFE
AF:
0.357
Gnomad OTH
AF:
0.315
GnomAD2 exomes
AF:
0.298
AC:
74786
AN:
251284
AF XY:
0.297
show subpopulations
Gnomad AFR exome
AF:
0.100
Gnomad AMR exome
AF:
0.258
Gnomad ASJ exome
AF:
0.400
Gnomad EAS exome
AF:
0.179
Gnomad FIN exome
AF:
0.442
Gnomad NFE exome
AF:
0.362
Gnomad OTH exome
AF:
0.341
GnomAD4 exome
AF:
0.334
AC:
488298
AN:
1461766
Hom.:
85644
Cov.:
47
AF XY:
0.329
AC XY:
239309
AN XY:
727194
show subpopulations
African (AFR)
AF:
0.102
AC:
3414
AN:
33478
American (AMR)
AF:
0.252
AC:
11258
AN:
44710
Ashkenazi Jewish (ASJ)
AF:
0.409
AC:
10678
AN:
26136
East Asian (EAS)
AF:
0.212
AC:
8412
AN:
39680
South Asian (SAS)
AF:
0.140
AC:
12063
AN:
86256
European-Finnish (FIN)
AF:
0.440
AC:
23499
AN:
53406
Middle Eastern (MID)
AF:
0.333
AC:
1919
AN:
5768
European-Non Finnish (NFE)
AF:
0.358
AC:
398095
AN:
1111938
Other (OTH)
AF:
0.314
AC:
18960
AN:
60394
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
20805
41609
62414
83218
104023
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
12398
24796
37194
49592
61990
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.276
AC:
41914
AN:
152060
Hom.:
6874
Cov.:
31
AF XY:
0.277
AC XY:
20558
AN XY:
74318
show subpopulations
African (AFR)
AF:
0.110
AC:
4566
AN:
41494
American (AMR)
AF:
0.278
AC:
4250
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
0.409
AC:
1419
AN:
3470
East Asian (EAS)
AF:
0.191
AC:
988
AN:
5176
South Asian (SAS)
AF:
0.126
AC:
605
AN:
4812
European-Finnish (FIN)
AF:
0.442
AC:
4676
AN:
10576
Middle Eastern (MID)
AF:
0.378
AC:
111
AN:
294
European-Non Finnish (NFE)
AF:
0.357
AC:
24257
AN:
67944
Other (OTH)
AF:
0.311
AC:
656
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1459
2918
4378
5837
7296
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
414
828
1242
1656
2070
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.323
Hom.:
13526
Bravo
AF:
0.260
Asia WGS
AF:
0.148
AC:
520
AN:
3478
EpiCase
AF:
0.366
EpiControl
AF:
0.362

ClinVar

Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Nov 10, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Immunodeficiency, common variable, 3 Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease.

Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not specified Benign:1
Jan 24, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 47% of patients studied by a panel of primary immunodeficiencies. Number of patients: 45. Only high quality variants are reported.

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.87
CADD
Benign
0.19
DANN
Benign
0.78
PhyloP100
-2.3
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs35979293; hg19: chr16-28944700; COSMIC: COSV61188690; COSMIC: COSV61188690; API